151 related articles for article (PubMed ID: 28512031)
21. Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.
Sarvagalla S; Singh VK; Ke YY; Shiao HY; Lin WH; Hsieh HP; Hsu JT; Coumar MS
J Comput Aided Mol Des; 2015 Jan; 29(1):89-100. PubMed ID: 25344840
[TBL] [Abstract][Full Text] [Related]
22. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and structure-activity relationships of 3,5-diaryl-1H-pyrazoles as inhibitors of arylamine N-acetyltransferase.
Fullam E; Talbot J; Abuhammed A; Westwood I; Davies SG; Russell AJ; Sim E
Bioorg Med Chem Lett; 2013 May; 23(9):2759-64. PubMed ID: 23518278
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2.
McBride C; Cheruvallath Z; Komandla M; Tang M; Farrell P; Lawson JD; Vanderpool D; Wu Y; Dougan DR; Plonowski A; Holub C; Larson C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2779-2783. PubMed ID: 27136719
[TBL] [Abstract][Full Text] [Related]
25. Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.
Markwalder JA; Seitz SP; Blat Y; Elkin L; Hunt JT; Pabalan JG; Jure-Kunkel MN; Vite GD; Covello K
Bioorg Med Chem Lett; 2017 Feb; 27(3):582-585. PubMed ID: 28003141
[TBL] [Abstract][Full Text] [Related]
26. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
27. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.
Laleu B; Gaggini F; Orchard M; Fioraso-Cartier L; Cagnon L; Houngninou-Molango S; Gradia A; Duboux G; Merlot C; Heitz F; Szyndralewiez C; Page P
J Med Chem; 2010 Nov; 53(21):7715-30. PubMed ID: 20942471
[TBL] [Abstract][Full Text] [Related]
28. Imidazopyridine and Pyrazolopiperidine Derivatives as Novel Inhibitors of Serine Palmitoyl Transferase.
Genin MJ; Gonzalez Valcarcel IC; Holloway WG; Lamar J; Mosior M; Hawkins E; Estridge T; Weidner J; Seng T; Yurek D; Adams LA; Weller J; Reynolds VL; Brozinick JT
J Med Chem; 2016 Jun; 59(12):5904-10. PubMed ID: 27213958
[TBL] [Abstract][Full Text] [Related]
29. Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors.
Kamata M; Yamashita T; Kina A; Tawada M; Endo S; Mizukami A; Sasaki M; Tani A; Nakano Y; Watanabe Y; Furuyama N; Funami M; Amano N; Fukatsu K
Bioorg Med Chem Lett; 2012 Jul; 22(14):4769-72. PubMed ID: 22677317
[TBL] [Abstract][Full Text] [Related]
30. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.
Kley JT; Mack J; Hamilton B; Scheuerer S; Redemann N
Bioorg Med Chem Lett; 2011 Oct; 21(19):5924-7. PubMed ID: 21873051
[TBL] [Abstract][Full Text] [Related]
31. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
Ho GD; Yang SW; Smotryski J; Bercovici A; Nechuta T; Smith EM; McElroy W; Tan Z; Tulshian D; McKittrick B; Greenlee WJ; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Jan; 22(2):1019-22. PubMed ID: 22222034
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
[TBL] [Abstract][Full Text] [Related]
33. Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
Jaikhan P; Buranrat B; Itoh Y; Chotitumnavee J; Kurohara T; Suzuki T
Bioorg Med Chem Lett; 2019 May; 29(10):1173-1176. PubMed ID: 30928196
[TBL] [Abstract][Full Text] [Related]
34. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
Orwat MJ; Qiao JX; He K; Rendina AR; Luettgen JM; Rossi KA; Xin B; Knabb RM; Wexler RR; Lam PY; Pinto DJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3341-5. PubMed ID: 24951330
[TBL] [Abstract][Full Text] [Related]
35. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
36. Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.
Dragovich PS; Fauber BP; Boggs J; Chen J; Corson LB; Ding CZ; Eigenbrot C; Ge H; Giannetti AM; Hunsaker T; Labadie S; Li C; Liu Y; Liu Y; Ma S; Malek S; Peterson D; Pitts KE; Purkey HE; Robarge K; Salphati L; Sideris S; Ultsch M; VanderPorten E; Wang J; Wei B; Xu Q; Yen I; Yue Q; Zhang H; Zhang X; Zhou A
Bioorg Med Chem Lett; 2014 Aug; 24(16):3764-71. PubMed ID: 25037916
[TBL] [Abstract][Full Text] [Related]
37. Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.
Horton JR; Liu X; Wu L; Zhang K; Shanks J; Zhang X; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Pohida K; Fang Y; Hu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Yan Q; Cheng X
J Med Chem; 2018 Apr; 61(7):3193-3208. PubMed ID: 29537847
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Li J; Wu F; Liu X; Zou Y; Chen H; Li Z; Zhang L
Eur J Med Chem; 2017 Nov; 140():20-30. PubMed ID: 28918097
[TBL] [Abstract][Full Text] [Related]
39. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
40. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
